Pharmacodynamic assessments in KMT2A-rearranged or NPM1-mutated AML patients has revealed swift downregulation of the stemness markers HOXA9, MEIS1, and PBX3, as well as the upregulation of differentiation marker CD11b. The gene discussed is MEIS1; the disease is acute myeloid leukemia.